Topics
Low-grade gliomas | Treatment | Clinical trials | Vorasidenib
Home > Publications > Topics > Low-grade gliomas > Treatment > Clinical trials > Vorasidenib
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J,
Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y,
Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick
W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA,
Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY,
Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
*Silvani A, Franceschi E.
A
new era after a long wait: Vorasetinib, an inhibitor of mutant
IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Tumori.
2024 Jan 2:3008916231217583. doi:
10.1177/03008916231217583. PMID:
38166539. Editorial. ˍ
RELATED
ARTICLE
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, et al.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Gatto L, Di Nunno V, Tosoni A,
Bartolini S, Ranieri L, Franceschi E.
Vorasidenib
in IDH1/2-mutant low-grade glioma: the grey zone of patient's
selection.
Front
Oncol. 2024 Jan
11;13:1339266. doi:
10.3389/fonc.2023.1339266. PMID:
38273856. Comment. ˍ
RELATED
ARTICLE
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J,
Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y,
Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick
W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA,
Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY,
Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti
R.
IDH inhibition in gliomas: from
preclinical models to clinical trials.
Nat
Rev Neurol. 2024 May 17. doi:
10.1038/s41582-024-00967-7. PMID:
38760442. Review. ˍ
Aduwo JY, McClelland S 3rd.
Censoring
Analysis of the INvestigating VorasiDenib In GliOma (INDIGO) Phase
III Randomized Controlled Trial.
Am
J Clin Oncol. 2025 Feb 14. doi:
10.1097/COC.0000000000001175. PMID:
39950862. Editorial. ˍ
RELATED
ARTICLE
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J,
Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y,
Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick
W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA,
Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY,
Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Lazarev S, Sindhu KK.
The INDIGO
Illusion: The Evidence Still Supports Chemoradiation Therapy in
Patients with Low-Grade Glioma.
Int
J Radiat Oncol Biol Phys. 2025 May 15;122(2):222. doi:
10.1016/j.ijrobp.2024.12.048. PMID:
40382161. Point of view. ˍ
Singh R, Palmer JD.
INDI-NO-GO: A
Recommendation for Caution with Use of Isocitrate Dehydrogenase
Inhibitors for High-Risk, Low-Grade Gliomas.
Int
J Radiat Oncol Biol Phys. 2025 May 15;122(2):223. doi:
10.1016/j.ijrobp.2025.01.019. PMID:
40382163. Point of view. ˍ